Key Highlights

  • Jupiter Neurosciences shares settled down about 25% to 28%, near $3.00 to $3.12, versus Friday's $4.18.
  • Nasdaq's Listing Qualifications staff told Jupiter on August 27 that it intends to delist the common stock.
  • The company missed the $35 million market-value-of-listed-securities test after a 180-day compliance period expired August 25.
  • Jupiter will appeal to a Hearings Panel, which typically stays delisting until the hearing concludes.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) shares settled down about 25% to 28%, near $3.00 to $3.12, versus Friday's $4.18, after Nasdaq's Listing Qualifications staff told the company on August 27 that it intends to delist the common stock from the Capital Market.

What Happened

Jupiter missed the $35 million market-value-of-listed-securities test under Rule 5550(b)(2) after a 180-day compliance clock that started February 26 expired August 25. The company also missed the alternative listing standards and will appeal to a Hearings Panel, which usually stays delisting until the hearing, though there is no guarantee the panel grants relief.

In the same filing, Nasdaq confirmed Jupiter regained compliance with the separate $1.00 minimum bid-price rule after ten straight closes at or above $1 between August 13 and 26, though that does not resolve the market-value deficiency.

Market Reaction

Shares fell sharply as investors weighed the loss of Nasdaq listing status, which can trigger reduced Liquidity and the exit of Index Funds and other institutional holders that require exchange listing.

Outlook

Until Jupiter's market Capitalization moves durably above the $35 million threshold, or the Hearings Panel grants a waiver, the stock's near-term trading is likely to be driven primarily by listing developments rather than clinical news.